Neurovascular Embolectomy Still Faces Major Hurdles in Europe Market growth restricted by limited reimbursement and lack of conclusive clinical data, according to Millennium Research Group
WALTHAM, Mass., Sept. 2 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the emerging market for neurovascular embolectomy devices for the treatment of acute ischemic stroke is poised for healthy yet conservative growth of close to 15% annually in Europe over the next 5 years. MRG's European Markets for Clot Management Devices 2009 report finds that although clinical safety data available to date has been positive for neurovascular embolectomy devices, more conclusive data is needed before widespread adoption occurs. Furthermore, as of mid-2009, reimbursement for neurovascular embolectomy procedures was limited in Europe.
Because infarcted brain tissue dies within minutes, early treatment is critical. Neurovascular embolectomy devices--including Concentric Medical's MERCI Retriever, the Penumbra System, and the Phenox Clot Retriever--extend the window of time for therapeutic intervention beyond the conventional 3 hours following onset of stroke symptoms approved for treatment with intravenous recombinant tissue plasminogen activator (IV rt-PA). This is noteworthy given the fact that most patients with suspected stroke in Europe arrive at the emergency department after the 3-hour time window. In addition, these devices provide a treatment alternative to patients in whom conventional thrombolysis might be ineffective or contraindicated.
"Despite satisfying unmet needs in acute ischemic stroke treatment, physician conservatism over these devices will continue to limit device adoption in Europe through 2013," says Darren Navarro, Senior Analyst at MRG. "Physicians seem to feel that although clinical results have been positive with respect to the safety and efficacy of cerebral revascularization, more conclusive data is needed demonstrating the beneficial effects of these devices on patient outcomes."
MRG's new report, European Markets for Clot Management Devices 2009, provides detailed five-year market forecasts for the adoption of neurovascular embolectomy devices in France, Germany, Italy, and the UK. Additionally, the report provides full coverage of the thrombectomy device, thrombolytic infusion catheter, and inferior vena cava filter markets with country-specific forecasts and analysis for each device market.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Amy Krohn Millennium Research Group 416-364-7776 x101 firstname.lastname@example.org Elizabeth Marshall Decision Resources Inc. 781-296-2563 email@example.com
SOURCE Millennium Research Group